Literature DB >> 1577877

Reversible inhibition of osteoclastic activity by bone-bound gallium (III).

H C Blair1, S L Teitelbaum, H L Tan, P H Schlesinger.   

Abstract

Gallium(III) is a new therapeutic agent for hypercalcemia. Ga3+ reduces osteoclast action, but how it inhibits the cell's physiology is unknown. In vivo, 7-12 microM Ga(III) reduces calcium release from bone, but surprisingly, 10-100 microM Ga3+ added to isolated avian osteoclasts did not reduce their degradation of L-(5-3H)-proline bone. 3H-proline labels bone collagen specifically, and collagenolysis is an excellent indicator of bone dissolution because collagen is the least soluble component of bone. Ga(III) greater than 100 microM inhibited osteoclasts in vitro, but also killed the cells. To resolve this apparent conflict, we measured 67Ga distribution between bone, cells, and media. Gallium binds avidly but slowly to bone fragments. One hundred micrograms of bone clears 60% of 1 microM gallium from 500 microliters of tissue culture medium, with steady state at greater than 24 h. Osteoclasts on bone inhibited gallium binding capacity approximately 40%, indicating a difference in available binding area and suggesting that osteoclasts protect their substrate from Ga binding. Less gallium binds to bone in serum-containing medium than in phosphate-buffered saline; 30% reduction of the affinity constant suggests that the serum containing medium competes with bone binding. Consequently, the effect of [Ga] on bone degradation was studied using accurately controlled amounts of Ga(III) pre-bound to the bone. Under these conditions, gallium sensitivity of osteoclasts is striking. At 2 days, 100 micrograms of bone pre-incubated with 1 ml of 1 microM Ga3+, with 10 pmoles Ga3+/micrograms bone, was degraded at 50% the rate of control bone; over 50 pM Ga3+/micrograms bone, resorption was essentially zero. In contrast, pre-treatment of bone with [Ga3+] as high as 15 microM had no significant effect on bone resorption rate beyond 3 days, indicating that gallium below approximately 150 pg/micrograms bone acts for a limited time and does not permanently damage the cells. We conclude that bone-bound Ga(III) from medium concentrations less than 15 microM inhibits osteoclasts reversibly, while irreversible toxicity occurs at solution [Ga3+] greater than 50 microM.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577877     DOI: 10.1002/jcb.240480409

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts.

Authors:  Elise Verron; Martial Masson; Solmaz Khoshniat; Laurence Duplomb; Yohann Wittrant; Marc Baud'huin; Zahi Badran; Bruno Bujoli; Pascal Janvier; Jean-Claude Scimeca; Jean-Michel Bouler; Jérôme Guicheux
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

2.  Osteogenic response and osteoprotective effects in vivo of a nanostructured titanium surface with antibacterial properties.

Authors:  F Ravanetti; R Chiesa; M C Ossiprandi; F Gazza; V Farina; F M Martini; R Di Lecce; G Gnudi; C Della Valle; J Gavini; A Cacchioli
Journal:  J Mater Sci Mater Med       Date:  2016-01-19       Impact factor: 3.896

3.  Bone tissue incorporates in vitro gallium with a local structure similar to gallium-doped brushite.

Authors:  M Korbas; E Rokita; W Meyer-Klaucke; J Ryczek
Journal:  J Biol Inorg Chem       Date:  2003-11-29       Impact factor: 3.358

4.  Microstructure and Mechanical Properties of Hot-Extruded Mg-Zn-Ga-(Y) Biodegradable Alloys.

Authors:  Viacheslav Bazhenov; Anna Li; Stanislav Tavolzhanskii; Andrey Bazlov; Natalia Tabachkova; Andrey Koltygin; Alexander Komissarov; Kwang Seon Shin
Journal:  Materials (Basel)       Date:  2022-10-02       Impact factor: 3.748

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.